Microwave coagulation therapy for hepatocellular carcinoma

Sato, Mariko; Watanabe, Yuji; Ueda, Shigeharu; Iseki, Sadafumi; Abe, Yashito; Sato, Norio; Kimura, Shigeru; Okubo, Keita; Onji, Morikazu

doi:10.1053/gast.1996.v110.pm8613057

Cited by 204 publications

(116 citation statements)

References 0 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…First, subcutaneous tumor models of an HCC cell line may not be relevant to HCCs in patients. However, in cases of nonsurgical procedures for HCC treatment in patients, such as percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, 49 and radiofrequency ablation, 50 administration of the current rAd vectors could be easily applicable immediately after the standard nonsurgical procedures to ensure tumor cell killing. Furthermore, rAd might elicit its immunogenicity or cytotoxicity 51 when administered in HCC patients, especially when spread out through blood flow.…”

Section: Discussionmentioning

confidence: 99%

Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma

et al. 2001

View full text Add to dashboard Cite

The therapeutic efficacy of herpes simplex virus thymidine kinase / ganciclovir ( HSV -tk / GCV ) system in many types of tumors is unsatisfactory due to the insufficient spread of gene transfer and insufficient cell killing. In the current study, we investigated whether adenovirally delivered monocyte chemoattractant protein ( MCP ) -1 potentiates the antitumor effects of the HSV -tk / GCV system in hepatocellular carcinoma ( HCC ) cells. Subcutaneous tumor foci of the human HCC cell line, HuH7, established in athymic mice were directly transduced with a recombinant adenovirus ( rAd ) harboring an HSV -tk gene driven by a human -fetoprotein promoter, followed by GCV administration. Subsequently, another rAd expressing MCP -1 under the universal CAG promoter was injected. The growth of tumors was markedly suppressed by codelivering HSV -tk and MCP -1 genes compared to that by either HSVtk / GCV or MCP -1 delivery. In the tumor tissues, monocyte / macrophage infiltration was detected immunohistochemically. The antitumor effects of the rAd expressing MCP -1 were markedly reduced by the administration of carrageenan, a compound known to inactivate macrophage. These results indicate that adenovirally delivered MCP -1 enhanced the antitumor effects of the HSV -tk / GCV system synergistically by recruitment / activation of macrophages in tumor tissues, suggesting an effective immunotherapy for HCC and other lineages of tumors when used adjuvantly with a suicide gene. Cancer Gene Therapy ( 2001 ) 8, 695 -704

show abstract

Section: Discussionmentioning

confidence: 99%

Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma

et al. 2001

View full text Add to dashboard Cite

show abstract

“…1 Cadaveric or living-related liver transplantation is another treatment option. 2,3 Several nonsurgical treatments have been attempted, including transcatheter arterial chemoembolization (TACE), transcatheter arterial embolization (TAE), 4,5 percutaneous ethanol injection (PEIT), 6,7 percutaneous microwave coagulation therapy (PMCT), 8 or most recently, radiofrequency ablation (RFA). 9,10 Sys-temic or hepatic arterial infusion chemotherapy 11,12 is also attempted for patients unable to undergo other surgical or nonsurgical treatment mainly because they have advanced stage disease.…”

mentioning

confidence: 99%

Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000

Toyoda

Kumada

Kiriyama

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe authors analyzed changes in the characteristics and survival rate of patients with hepatocellular carcinoma (HCC) in the past 25 years.METHODSTrends in clinical characteristics and survival rate of patients with HCC were evaluated retrospectively based on data from 1365 patients who were diagnosed, treated, and followed between 1976 and 2000.RESULTSBetween 1976–1995, the number of patients with smaller tumors, a less advanced tumor stage, and with a lower Child–Pugh class increased markedly. No differences were observed in the distributions of these three factors between the periods 1991–1995 and 1996–2000. The year of HCC diagnosis, tumor size, tumor stage, Child–Pugh class, and the kind of initial treatment received correlated significantly with patient survival rates by multivariate analysis. The year of HCC diagnosis was found to contribute independently to the improvement in patient survival rates. Using the Kaplan–Meier comparison, the time periods during which the highest patient survival rates occurred were found to be 1991–1995/1996–2000, 1986–1990, and 1976–1985, in that order. The authors did not observe a difference with regard to survival rates between patients in the 1991–1995 and 1996–2000 groups.CONCLUSIONSThe characteristics of patients with HCC changed dramatically from 1976 to 1995 (but not in the past 10 years) toward the earlier detection of HCC. This contributed to the improvement noted in patient survival rates during this period. The year of HCC diagnosis was found to be an independent factor for the improved survival rates by multivariate analysis. This indicated that the progress of treatment and care for patients with HCC contributed to the annual improvement in patient survival rates. Cancer 2004. © 2004 American Cancer Society.

show abstract

“…48,49 Thus, better gene delivery methods need to be developed to treat large tumors. However, in cases of nonsurgical procedures for HCC treatment in patients, such as percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy 50 and radiofrequency ablation, 51 administration of the described recombinant Ad vectors could be easily applicable immediately after these standard nonsurgical procedures are complete the help promote tumor cell killing. The systemic administration of the high doses of rAds could also cause severe unexpected side effects.…”

Section: Discussionmentioning

confidence: 99%

Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma

et al. 2003

View full text Add to dashboard Cite

The efficacy of the suicide gene therapy using the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system for the treatment of cancer is limited because of the insufficient gene transfer and the low killing activity. To enhance the antitumor activity, we determined whether recombinant adenovirus vector (rAd)s expressing both HSV-tk and monocyte chemoattractant protein-1 (MCP-1) genes could potentiate the destruction of hepatocellular carcinoma (HCC). The rAd Ad-tk-MCP1 harboring HSVtk and MCP-1 genes in sequence under the universal CAG promoter was constructed with a bicistronic unit including the encephalomyocarditis virus-internal ribosomal entry site. The levels of HSV-tk expression and GCV-sensitive tumoricidal activity of Ad-tk-MCP1 were comparable to those of rAd expressing HSV-tk alone. The growth of subcutaneous tumors in athymic nude mice was markedly suppressed when tumors were treated with Ad-tk-MCP1 as opposed to another bicistronic vector Ad-MCP1-tk, rAd expressing either HSV-tk or MCP-1, or both of these vectors. The antitumor effects of Ad-tkMCP1 may be dependent on the activation of macrophages, since the recruitment of macrophages was observed tumor necrosis factor-a production was enhanced in the tumor tissue. Furthermore, the enhanced antitumor effect was abolished by inactivating macrophages with carrageenan treatment. These results demonstrated that a bicistronic rAd harboring both suicide and chemokine genes in sequence exerted the enhanced, macrophage-dependent, antitumor effects in a model of HCC and support the use of this strategy for the treatment of HCC.

show abstract

Microwave coagulation therapy for hepatocellular carcinoma

Cited by 204 publications

References 0 publications

Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma

Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma

Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000

Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma

Contact Info

Product

Resources

About